natgillin/translations-raw huggingface dataset:
► Hver gang du bruger en ny NovoMix 50 Penfill (før du monterer cylinderampullen i insulindispenseringssystemet)
► Every time you use a new NovoMix 50 Penfill (before you put the cartridge into the insulin delivery system)
I sjældne tilfælde kan reaktioner på injektionsstedet nødvendiggøre ophør af behandling med NovoMix 30.
On rare occasions, injection site reactions may require discontinuation of NovoMix 30.
NovoMix 50 må ikke anvendes i insulin-infusionspumper.
NovoMix 50 is not to be used in insulin infusion pumps.
NovoMix 70 begynder at nedsætte blodsukkeret 10-20 minutter efter injektion, den maksimale effekt ses mellem 1 og 4 timer efter injektionen, og virkningen varer op til 14-24 timer.
NovoMix 70 will start to lower your blood sugar 10-20 minutes after you inject it, the maximum effect occurs between 1 and 4 hours after the injection, and the effect lasts for up to 14-24 hours.
Insulin aspart i den opløselige fase af NovoMix 30 indeholder 30% af den samlede insulin og absorberes hurtigere fra subkutis end den opløselige insulinkomponent i bifasisk humant insulin.
The insulin aspart in the soluble phase of NovoMix 30 comprises 30% of the total insulin; this is absorbed more rapidly from the subcutaneous layer than the soluble insulin component of biphasic human insulin.
NovoMix 30 begynder at nedsætte blodsukkeret 10-20 minutter efter injektion, den maksimale effekt ses mellem 1 og 4 timer efter injektionen, og virkningen varer op til 24 timer.
NovoMix 30 will start to lower your blood sugar 10-20 minutes after you inject it, the maximum effect occurs between 1 and 4 hours after the injection, and the effect lasts for up to 24 hours.
► Hvis du behandles med NovoMix 70 Penfill sammen med en anden insulintype i Penfill cylinderampul, skal du anvende to dispenseringssystemer, et til hver insulintype.
► If you are treated with NovoMix 70 Penfill and another insulin Penfill cartridge, you should use two insulin delivery systems, one for each type of insulin.
NovoMix 70 er et bifasisk insulin, som indeholder 70 % opløseligt insulin aspart.
NovoMix 70 is a biphasic insulin, which contains 70% soluble insulin aspart.
Nåle forhandles separat
Needles are not included
NovoMix 30 er et bifasisk insulin, som indeholder 30% opløseligt insulin aspart.
NovoMix 30 is a biphasic insulin, which contains 30% soluble insulin aspart.
NovoMix 30 må ikke anvendes i insulininfusionspumper.
NovoMix 30 is not to be used in insulin infusion pumps.
► Hvis du behandles med NovoMix 50 Penfill sammen med en anden insulintype i Penfill cylinderampul, skal du anvende to dispenseringssystemer, et til hver insulintype.
► If you are treated with NovoMix 50 Penfill and another insulin Penfill cartridge, you should use two insulin delivery systems, one for each type of insulin.
► Hver gang du bruger en ny NovoMix 30 Penfill (før du monterer cylinderampullen i insulindispenseringssystemet)
► Every time you use a new NovoMix 30 Penfill (before you put the cartridge into the insulin delivery system)
NovoMix 30 er kun beregnet til subkutan administration.
NovoMix 30 is for subcutaneous administration only.
NovoMix 30 dosisjustering
NovoMix 30 dose adjustment
► Efter hver injektion, skal nålen fjernes og kasseres, og NovoMix 70 skal opbevares uden nålen påsat.
► After each injection, be sure to remove and discard the needle and store NovoMix 70 without the needle attached.
Det er vigtigt at understrege over for patienten, at NovoMix 70 suspensionen skal opblandes umiddelbart før brug.
The necessity of resuspending the NovoMix 70 suspension immediately before use is to be stressed to the patient.
NovoMix 70 er beregnet til injektion under huden (subkutant).
NovoMix 70 is for injection under the skin (subcutaneously).
Før du bruger NovoMix 30
Before using NovoMix 30
Hos type 1 diabetikere blev maksimal serumkoncentration på 721 ± 184 opnået ca. 60 minutter efter injektion efter subkutan injektion af 0,30 enheder/kg legemsvægt.
In type 1 patients with diabetes a mean maximum serum concentration of 721 ± 184 pmol/l was reached about 60 minutes after a subcutaneous dose of 0.30 unit/kg body weight.
► Hvis du behandles med NovoMix 30 Penfill sammen med en anden insulintype i Penfill cylinderampul, skal du anvende to dispenseringssystemer, et til hver insulintype.
► If you are treated with NovoMix 30 Penfill and another insulin Penfill cartridge, you should use two insulin delivery systems, one for each type of insulin.
Det anbefales, at insulinet opblandes som instrueret, hver gang du bruger en ny NovoMix 70 Penfill.
It is recommended to resuspend the insulin as instructed every time you use a new NovoMix 70 Penfill.
Suspensionen indeholder hurtigvirkende og middellangt virkende insulin aspart i forholdet 30/70.
The suspension contains rapid-acting and intermediate-acting insulin aspart in the ratio 30/70.
NovoMix 30 Penfill 100 enheder/ml, injektionsvæske, suspension i cylinderampul NovoMix 30 FlexPen 100 enheder/ml, injektionsvæske, suspension i fyldt pen
NAME OF THE MEDICINAL PRODUCT NovoMix 30 Penfill 100 units/ml suspension for injection in cartridge NovoMix 30 FlexPen 100 units/ml suspension for injection in pre-filled pen
NovoMix 50 er et moderne insulin (en insulinanalog) med både en hurtigtvirkende og en mellemlang virkende effekt i forholdet 50/50.
NovoMix 50 is a modern insulin (insulin analogue) with both a rapid-acting and an intermediateacting effect, in the ratio 50/50.
Når NovoMix 70 injiceres subkutant, indtræder virkningen inden for 10-20 minutter efter injektion.
When NovoMix 70 is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection.
NovoMix 30 Penfill og NovoMix 30 FlexPen:
NovoMix 30 Penfill and NovoMix 30 FlexPen:
Det er vigtigt at understrege over for patienten, at NovoMix 30 suspensionen skal opblandes umiddelbart før brug.
The necessity of resuspending the NovoMix 30 suspension immediately before use is to be stressed to the patient.
Når NovoMix 70 anvendes sammen med tabletter mod sukkersyge, skal dosis justeres.
When NovoMix 70 is used in combination with metformin the dose should be adjusted.
NovoMix må ikke injiceres, hvis hypoglykæmi er konstateret, eller hvis hypoglykæmi mistænkes.
In case of hypoglycaemia or if hypoglycaemia is suspected, NovoMix must not be injected.
► Efter hver injektion, skal nålen fjernes og kasseres, og NovoMix 50 skal opbevares uden nålen påsat.
► After each injection, be sure to remove and discard the needle and store NovoMix 50 without the needle attached.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE YDRE KARTON (CYLINDERAMPUL, Penfill)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (CARTRIDGE.
Når NovoMix 50 anvendes sammen med tabletter mod sukkersyge, skal dosis justeres.
When NovoMix 50 is used in combination with metformin the dose should be adjusted.
Det anbefales, at opblande insulinet som beskrevet, hver gang du bruger en ny pen.
It is recommended to resuspend the insulin as instructed every time you use a new pen.
6.6 Regler for destruktion og anden håndtering Efter, at NovoMix 70 Penfill eller NovoMix 70 FlexPen er taget ud af køleskabet, bør NovoMix 70 Penfill eller NovoMix 70 FlexPen opnå stuetemperatur inden insulinet opblandes som beskrevet ved brug første gang.
After removing NovoMix 70 Penfill or NovoMix 70 FlexPen from the refrigerator, it is recommended to allow NovoMix 70 Penfill or NovoMix 70 FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
NovoMix 70 er kun beregnet til subkutan administration.
NovoMix 70 is for subcutaneous administration only.
1 x 3 ml cylinderampul 5 x 3 ml cylinderampuller 10 x 3 ml cylinderampuller
1 x 3 ml cartridge 5 x 3 ml cartridges 10 x 3 ml cartridges
Suspensionen indeholder hurtigvirkende og middellangt virkende insulin aspart i forholdet 70/30.
The suspension contains rapid-acting and intermediate-acting insulin aspart in the ratio 70/30.
Hos frivillige raske personer blev en gennemsnitlig maksimal serumkoncentration på 140 ± 32 pmol/l opnået ca. 60 minutter efter subkutan injektion af 0,20 enheder/kg legemsvægt.
In healthy volunteers, a mean maximum serum concentration of 140 ± 32 pmol/l was reached about 60 minutes after a subcutaneous dose of 0.20 unit/kg body weight.
NovoMix 50 er et bifasisk insulin, som indeholder 50% opløseligt insulin aspart.
NovoMix 50 is a biphasic insulin, which contains 50% soluble insulin aspart.
Glucoseniveau før måltider
Pre-meal blood glucose level
• Dyrker mindre motion end du plejer.
• Exercise less than usual.
Det skal du vide, før du begynder at bruge NovoMix 70
What you need to know before you use NovoMix 70
NovoMix 50 Penfill og NovoMix 50 FlexPen:
NovoMix 50 Penfill and NovoMix 50 FlexPen:
Opbevar cylinderampullen i den ydre karton for at beskytte mod lys.
Keep the cartridge in the outer carton in order to protect it from light.
Det er vigtigt at understrege over for patienten, at NovoMix 50 suspensionen skal opblandes umiddelbart før brug.
The necessity of resuspending the NovoMix 50 suspension immediately before use is to be stressed to the patient.
Opbevar FlexPen med penhætten påsat for at beskytte mod lys.
Keep the cap on FlexPen in order to protect it from light.
NovoMix 50 er beregnet til injektion under huden (subkutant).
NovoMix 50 is for injection under the skin (subcutaneously).
Den kliniske erfaring med NovoMix 70 under graviditet er begrænset.
There is limited clinical experience with NovoMix 70 in pregnancy.
Hos frivillige raske personer blev en gennemsnitlig maksimal serumkoncentration på 445 ± 135 pmol/l opnået ca. 60 minutter efter subkutan injektion af 0,30 enheder/kg legemsvægt.
In healthy volunteers, a mean maximum serum concentration of 445 ± 135 pmol/l was reached about 60 minutes after a subcutaneous dose of 0.30 unit/kg body weight.
NovoMix 70 må ikke udsættes for overdreven varme og direkte lys.
NovoMix 70 must be protected from excessive heat and light.
NovoMix 30 er beregnet til injektion under huden (subkutant).
NovoMix 30 is for injection under the skin (subcutaneously).
NovoMix 50 er en blanding bestående af 50% opløseligt insulin aspart og 50% protaminkrystalliseret insulin aspart.
NovoMix 50 is a mixture consisting of 50% soluble insulin aspart and 50% insulin aspart crystallised with protamine.
NovoMix 70 anvendes til at reducere det høje blodsukkerniveau hos patienter med sukkersyge (diabetes mellitus).
NovoMix 70 is used to reduce the high blood sugar level in patients with diabetes mellitus (diabetes).
En fyldt pen indeholder 3 ml svarende til 300 enheder.
1 pre-filled pen contains 3 ml equivalent to 300 units.
Det skal du vide, før du begynder at bruge NovoMix 50
What you need to know before you use NovoMix 50
NovoMix 50 må ikke udsættes for overdreven varme og direkte lys.
NovoMix 50 must be protected from excessive heat and light.
NovoMix 50 er en bifasisk suspension af 50% opløseligt insulin aspart (human insulinanalog med hurtigt indsættende virkning) og 50% protaminkrystalliseret insulin aspart (human insulinanalog med middellang virkningstid).
NovoMix 50 is a biphasic suspension of 50% soluble insulin aspart (rapid-acting human insulin analogue) and 50% protamine-crystallised insulin aspart (intermediate-acting human insulin analogue).
NovoMix 50 FlexPen er en fyldt, farvekodet engangspen til flergangsbrug, som indeholder en blanding af hurtigtvirkende og mellemlangt virkende insulin aspart i forholdet 50/50.
NovoMix 50 FlexPen is a pre-filled, colour-coded, disposable pen containing a mixture of rapid-acting and intermediate-acting insulin aspart in the ratio 50/50.
Når NovoMix 30 injiceres subkutant, indtræder virkningen inden for 10-20 minutter efter injektion.
When NovoMix 30 is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection.
1 cylinderampul indeholder 3 ml svarende til 300 enheder
1 cartridge contains 3 ml equivalent to 300 units
NovoMix 50 anvendes til at reducere det høje blodsukkerniveau hos patienter med sukkersyge (diabetes mellitus).
NovoMix 50 is used to reduce the high blood sugar level in patients with diabetes mellitus (diabetes).
► Efter hver injektion, skal nålen fjernes og kasseres, og NovoMix 30 skal opbevares uden nålen påsat.
► After each injection, be sure to remove and discard the needle and store NovoMix 30 without the needle attached.
Patienter, der skifter til NovoMix 70 fra en anden insulintype, skal muligvis have et øget antal daglige injektioner eller en ændret dosis i forhold til dosis af de sædvanlige insulinpræparater.
Patients transferred to NovoMix 70 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products.
NovoMix 70 er et moderne insulin (en insulinanalog) med både en hurtigtvirkende og en mellemlang virkende effekt i forholdet 70/30.
NovoMix 70 is a modern insulin (insulin analogue) with both a rapid-acting and an intermediateacting effect, in the ratio 70/30.
NovoMix 30 leveres som en suspension til injektion i en fyldt pen.
NovoMix 30 is presented as a suspension for injection in a pre-filled pen.
Hos frivillige raske personer blev en gennemsnitlig maksimal serumkoncentration på 645 ± 185 pmol/l opnået ca. 60 minutter efter subkutan injektion af 0,30 enheder/kg legemsvægt.
In healthy volunteers, a mean maximum serum concentration of 645 ± 185 pmol/l was reached about 60 minutes after a subcutaneous dose of 0.30 unit/kg body weight.
Når NovoMix 50 injiceres subkutant, indtræder virkningen inden for 10-20 minutter efter injektion.
When NovoMix 50 is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection.
De farmakokinetiske egenskaber for NovoMix 30 er ikke blevet undersøgt hos ældre patienter eller hos patienter med nedsat nyre- eller leverfunktion.
The pharmacokinetics of NovoMix 30 have not been investigated in elderly patients or in patients with renal or hepatic impairment.
NovoMix 70 Penfill 100 enheder/ml
NovoMix 70 Penfill 100 units/ml
Den kliniske erfaring med NovoMix 30 under graviditet er begrænset.
There is limited clinical experience with NovoMix 30 in pregnancy.
NovoMix 50 administreres subkutant ved injektion i låret eller abdominalvæggen.
NovoMix 50 is administered subcutaneously by injection in the thigh or in the abdominal wall.
NovoMix 30 må ikke udsættes for overdreven varme og direkte lys.
NovoMix 30 must be protected from excessive heat and light.
Brug af anden medicin sammen med NovoMix 70
Other medicines and NovoMix 70
Subkutan anvendelse
STATEMENT OF ACTIVE SUBSTANCE
De farmakokinetiske egenskaber for NovoMix 70 er ikke blevet undersøgt hos børn, ældre patienter eller patienter med nedsat nyre- eller leverfunktion.
The pharmacokinetics of NovoMix 70 have not been investigated in paediatrics, elderly patients or in patients with renal or hepatic impairment.
NovoMix 30 er et moderne insulin (en insulinanalog) med både en hurtigtvirkende og en mellemlang virkende effekt i forholdet 30/70.
NovoMix 30 is a modern insulin (insulin analogue) with both a rapid-acting and an intermediateacting effect, in the ratio 30/70.
NovoMix 30 Penfill 100 enheder/ml
NovoMix 30 Penfill 100 units/ml
Brug af anden medicin sammen med NovoMix 50
Other medicines and NovoMix 50
NovoMix 70 administreres subkutant ved injektion i låret eller abdominalvæggen.
NovoMix 70 is administered subcutaneously by injection in the thigh or in the abdominal wall.
Patienter, der skifter til NovoMix 30 fra en anden insulintype, skal muligvis have et øget antal daglige injektioner eller en ændret dosis i forhold til dosis af de sædvanlige insulinpræparater.
Patients transferred to NovoMix 30 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products.
Pakningsstørrelser med 5 eller 10 cylinderampuller med 3 ml.
Pack sizes of 5 and 10 cartridges of 3 ml.
Patienter, der skifter til NovoMix 50 fra en anden insulintype, skal muligvis have et øget antal daglige injektioner eller en ændret dosis i forhold til dosis af de sædvanlige insulinpræparater.
Patients transferred to NovoMix 50 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products.
Brugervejledning til NovoMix 70 injektionsvæske, suspension i FlexPen.
Instruction on how to use NovoMix 70 suspension for injection in FlexPen.
Det skal du vide, før du begynder at bruge NovoMix 30
What you need to know before you use NovoMix 30
Hvis det er nødvendigt, kan NovoMix 70 gives lige efter et måltid.
When necessary, NovoMix 70 can be given soon after a meal.
Det anbefales, at insulinet opblandes som instrueret, hver gang du bruger en ny NovoMix 50 Penfill.
It is recommended to resuspend the insulin as instructed every time you use a new NovoMix 50 Penfill.
Den kliniske erfaring med NovoMix 50 under graviditet er begrænset.
There is limited clinical experience with NovoMix 50 in pregnancy.
NovoMix 70 forekommer som en hvid suspension til injektion.
NovoMix 70 is presented as a suspension for injection.
Hvordan NovoMix 30 skal injiceres
How to inject NovoMix 30
Anvend ikke pennen, hvis det opblandede insulin ikke ser ensartet hvidt, uklart og vandigt ud.
Do not use the pen if the resuspended insulin does not look uniformly white, cloudy and aqueous.
Det anbefales, at insulinet opblandes som instrueret, hver gang du bruger en ny NovoMix 30 Penfill.
It is recommended to resuspend the insulin as instructed every time you use a new NovoMix 30 Penfill.
NovoMix 50 Penfill 100 enheder/ml
NovoMix 50 Penfill 100 units/ml
NovoMix 30 administreres subkutant ved injektion i låret eller abdominalvæggen.
NovoMix 30 is administered subcutaneously by injection in the thigh or in the abdominal wall.
• Skjoldbruskkirtelhormoner (til behandling af sygdomme i skjoldbruskkirtlen)
• Thyroid hormones (used to treat thyroid gland disorders)
NovoMix 70 FlexPen er en fyldt, farvekodet engangspen til flergangsbrug, som indeholder en blanding af hurtigtvirkende og mellemlangt virkende insulin aspart i forholdet 70/30.
NovoMix 70 FlexPen is a pre-filled, colour-coded, disposable pen containing a mixture of rapid-acting and intermediate-acting insulin aspart in the ratio 70/30.
INFORMATION I BRAILLE-SKRIFT NovoMix 70 FlexPen
INFORMATION IN BRAILLE NovoMix 70 FlexPen
NovoMix 70 er en blanding bestående af 70% opløseligt insulin aspart og 30% protaminkrystalliseret insulin aspart.
NovoMix 70 is a mixture consisting of 70% soluble insulin aspart and 30% insulin aspart crystallised with protamine.
Hvis det er nødvendigt, kan NovoMix 50 gives lige efter et måltid.
When necessary, NovoMix 50 can be given soon after a meal.
NovoMix 70 er en bifasisk suspension af 70% opløseligt insulin aspart (human insulinanalog med hurtigt indsættende virkning) og 30% protaminkrystalliseret insulin aspart (human insulinanalog med middellang virkningstid).
NovoMix 70 is a biphasic suspension of 70% soluble insulin aspart (rapid-acting human insulin analogue) and 30% protamine-crystallised insulin aspart (intermediate-acting human insulin analogue).
(EMAs) hjemmeside http://www.ema.europa.eu
Detailed information on this medicine is available on the website of the European Medicines Agency: http://www.ema.europa.eu.
De farmakokinetiske egenskaber for NovoMix 50 er ikke blevet undersøgt hos børn, ældre patienter eller patienter med nedsat nyre- eller leverfunktion.
The pharmacokinetics of NovoMix 50 have not been investigated in paediatrics, elderly patients or in patients with renal or hepatic impairment.
Når det er nødvendigt, kan NovoMix 30 indgives umiddelbart efter et måltid.
When necessary, NovoMix 30 can be given soon after a meal.
Dette lægemiddel må ikke anvendes, hvis den opblandede væske ikke er ensartet hvid, uklar og vandig.
Do not use this medicinal product if you notice that the resuspended liquid is not uniformly white, cloudy and aqueous.
NovoMix 70 FlexPen er en fyldt pen (farvekodet) beregnet til brug sammen med NovoFine eller NovoTwist nåle.
NovoMix 70 FlexPen is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist needles.
Brugervejledning til NovoMix 50 injektionsvæske, suspension i FlexPen.
Instruction on how to use NovoMix 50 suspension for injection in FlexPen.
Brug af anden medicin sammen med NovoMix 30
Other medicines and NovoMix 30
NovoMix 30 er en blanding bestående af 30% opløseligt insulin aspart og 70% protaminkrystalliseret insulin aspart.
NovoMix 30 is a mixture consisting of 30% soluble insulin aspart and 70% insulin aspart crystallised with protamine.
MARKEDSFØRINGSTILLADELSESNUMRE EU/1/00/142/020 1 pen med 3 ml EU/1/00/142/021 5 penne med 3 ml EU/1/00/142/022 10 penne med 3 ml
MARKETING AUTHORISATION NUMBERS EU/1/00/142/020 1 pen of 3 ml EU/1/00/142/021 5 pens of 3 ml EU/1/00/142/022 10 pens of 3 ml
NovoMix 30 FlexPen er en fyldt, farvekodet engangspen til flergangsbrug, som indeholder en blanding af hurtigtvirkende og mellemlangt virkende insulin aspart i forholdet 30/70.
NovoMix 30 FlexPen is a pre-filled, colour-coded, disposable pen containing a mixture of rapid-acting and intermediate-acting insulin aspart in the ratio 30/70.
Pakningsstørrelser med 1, 5 eller 10 cylinderampuller med 3 ml.
Pack sizes of 1, 5 and 10 cartridges of 3 ml.
50% opløselig insulin aspart og 50% protaminkrystalliseret insulin aspart s.c. anvendelse
50% soluble insulin aspart and 50% insulin aspart crystallised with protamine SC use
INFORMATION I BRAILLE-SKRIFT NovoMix 30 FlexPen
INFORMATION IN BRAILLE NovoMix 30 FlexPen
NovoMix 30 er en bifasisk suspension af 30% opløseligt insulin aspart (human insulinanalog med hurtigt indsættende virkning) og 70% protaminkrystalliseret insulin aspart (human insulinanalog med middellang virkningstid).
NovoMix 30 is a biphasic suspension of 30% soluble insulin aspart (rapid-acting human insulin analogue) and 70% protamine-crystallised insulin aspart (intermediate-acting human insulin analogue).
INFORMATION I BRAILLE-SKRIFT NovoMix 30 Penfill
INFORMATION IN BRAILLE NovoMix 30 Penfill
INFORMATION I BRAILLE-SKRIFT NovoMix 70 Penfill
INFORMATION IN BRAILLE NovoMix 70 Penfill
En cylinderampul indeholder 3 ml svarende til 300 enheder.
1 cartridge contains 3 ml equivalent to 300 units.
NovoMix 70 forekommer som en hvid suspension til injektion i en fyldt pen.
NovoMix 70 is presented as a suspension for injection in a pre-filled pen.
Hvordan NovoMix 50 skal injiceres
How to inject NovoMix 50
NovoMix 30 FlexPen er en fyldt pen (farvekodet) beregnet til brug sammen med NovoFine eller NovoTwist nåle.
NovoMix 30 FlexPen is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist needles.
INFORMATION I BRAILLE-SKRIFT NovoMix 50 FlexPen
INFORMATION IN BRAILLE NovoMix 50 FlexPen
Frekvensenskategorierne er defineret i henhold til følgende konvention: Meget almindelig (≥1/10), almindelig (≥1/100 til <1/10), ikke almindelig (≥1/1.000 til ≤1/100), sjælden (≥1/10.000 til ≤1/1.000), meget sjælden (≤1/10.000), ikke kendt (kan ikke estimeres ud fra tilgængelige data).
(≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Hvordan NovoMix 70 skal injiceres
How to inject NovoMix 70
MARKEDSFØRINGSTILLADELSESNUMRE EU/1/00/142/014 1 pen med 3 ml EU/1/00/142/015 5 penne med 3 ml EU/1/00/142/016 10 penne med 3 ml
MARKETING AUTHORISATION NUMBERS EU/1/00/142/014 1 pen of 3 ml EU/1/00/142/015 5 pens of 3 ml EU/1/00/142/016 10 pens of 3 ml
Det skal du vide, før du begynder at bruge NovoMix 70 Sådan skal du bruge NovoMix 70
What NovoMix 70 is and what it is used for What you need to know before you use NovoMix 70 How to use NovoMix 70
NovoMix 50 FlexPen er en fyldt pen (farvekodet) beregnet til brug sammen med NovoFine eller NovoTwist nåle.
NovoMix 50 FlexPen is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist needles.
► Nåle og NovoMix 70 FlexPen må ikke deles med andre.
► Needles and NovoMix 70 FlexPen must not be shared.
Pakningsstørrelser med 1, 5 og 10 fyldte penne med 3 ml.
Pack sizes of 1, 5 and 10 pre-filled pens of 3 ml.
► Nåle og NovoMix 50 FlexPen må ikke deles med andre.
► Needles and NovoMix 50 FlexPen must not be shared.